Please assess the completion status of the following clinical trial:

Trial Title: Impact of Colchicine in Hospitalized Colombian Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years old.~* Laboratory-confirmed SARS-CoV-2 infection: infection confirmed with nasopharyngeal swab by positive RT PCR in the last 48 hours.~* Hospital admission for COVID-19 in the previous 48 hours.~* Clinical stage 3 (no supplemental oxygen requirement) or 4 (supplemental oxygen requirement for nasal contact lenses or mask) of the WHO classification (see ANNEX 2).~* The patient must be able and willing to provide informed written consent before performing study procedures.~* Patient confirmed to covid19 as positive by positive PCR test~Exclusion Criteria:~* Pregnancy, nursing mothers, and women of childbearing potential who are unable to use adequate contraception.~* Known hypersensitivity or other clear contraindication to the use of colchicine.~* History of end-stage renal disease (eGFR \<30 ml / min / 1.73 m2).~* Medical history of cirrhosis (Child-Pugh C), liver failure, chronic active hepatitis, or severe liver disease defined by alanine aminotransferase (ALT) or aspartate aminotransferase (AST)\> 5 times the upper limit of normal.~* History of pre-existing neuromuscular disease.~* Previous severe hematologic disease or bleeding disorders.~* Inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea, or malabsorptive syndrome.~* Colchicine treatment for other indications.~* Treatment with immunosuppressive/immunomodulatory agents, including glucocorticoids, antivirals, antimalarials, and IL 6 antagonists for 30 days prior to enrollment.~* Use of other investigational drugs at the time of inclusion, or during the 30 days prior to inclusion.~* Any medical condition or disease that, in the opinion of the investigator, may place the patient at unacceptable risk to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COLHICINE PLUS STANDARD TREATMENT (Type: ACTIVE_COMPARATOR): Patients treated in the exposed group will consist of a decreasing dose of colchicine: a dose of 1.5 mg orally on the first day (initial 1 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
- STANDARD TREATMENT (Type: PLACEBO_COMPARATOR): In this case, the centers where the patients will be included adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases), and to standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).